- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02543567
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
December 7, 2023 updated by: Janssen Vaccines & Prevention B.V.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime-Boost Regimen of Ad26.ZEBOV and MVA-BN®-Filo in Healthy Adult Subjects
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen with the recently released batches of Ad26.ZEBOV and MVA-BN-Filo in terms of humoral immune response against the Ebola virus (EBOV) GP (glycoprotein) as measured by enzyme-linked immunosorbent assay (ELISA) at 21 days post boost.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate safety and immunogenicity of Ad26.ZEBOV and MVA-BN-Filo at different dose levels, administered to healthy adults participants.
The study consists of a Screening period of up to 6 weeks, vaccinations on Day 1 and Day 57, and a post-vaccination phase until the 6 months post-boost visit (Day 237).
The participants will be randomized at baseline (on Day 1) in a 2:2:2:1 ratio to Groups 1, 2, 3 and 4. Safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
525
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States
-
-
California
-
San Diego, California, United States
-
-
Florida
-
Melbourne, Florida, United States
-
-
Illinois
-
Peoria, Illinois, United States
-
-
Indiana
-
Mishawaka, Indiana, United States
-
-
Maryland
-
Rockville, Maryland, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion criteria :
- Must be healthy in the Investigator's clinical judgment on the basis of medical history, physical examination, electrocardiogram (ECG) and vital signs performed at Screening
- Must be healthy on the basis of clinical laboratory tests performed at Screening
- Before randomization, a woman must be either of childbearing potential and practicing (or intending to practice) a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies, beginning at least 28 days prior to vaccination OR not of childbearing potential: postmenopausal [greater than (>)] 45 years of age with amenorrhea for at least 2 years or any age with amenorrhea for at least 6 months, and a serum follicle stimulating hormone (FSH) level >40 international unit per milliliter (IU/L); permanently sterilized (for example, bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy
- Woman of childbearing potential must have a negative serum [beta-human chorionic gonadotropin (beta-hCG)] at Screening and a negative urine beta-hCG pregnancy test immediately prior to each study vaccine administration
- Man who is sexually active with a woman of childbearing potential and has not had a vasectomy performed more than 1 year prior to Screening must be willing to use condoms for sexual intercourse beginning prior to enrollment, in addition to the birth control method used by the female partner
Exclusion criteria:
- Having received a candidate Ebola vaccine
- Diagnosed with Ebola virus disease, or prior exposure to Ebola virus, including travel to West Africa less than 1 month prior to Screening. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone
- Having received any experimental candidate adenovirus serotype 26 (vector: Ad26) or Modified Vaccinia Ankara (MVA)- based vaccine in the past
- Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines) including known allergy to egg, egg products and aminoglycosides
- Presence of acute illness or temperature greater than or equal to (>=) 38.0 (°C) centigrade on Day 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf.
U.] single dose IM injection on Day 57
|
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf.
U.] once on Day 57
|
Experimental: Group 2
Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf.
U single dose IM injection on Day 57
|
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf.
U. once on Day 57
|
Experimental: Group 3
Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf.
U. single dose IM injection on Day 57
|
MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5*10^7 Inf.
U. once on Day 57
Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
|
Experimental: Group 4
Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
|
One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Responses to the Study Vaccine Regimens against Ebola virus (EBOV) Glycoprotein (GP) using EBOV GP protein Enzyme-linked Immunosorbent Assay (ELISA)
Time Frame: At 21 days post boost vaccination
|
The humoral immune response will be assessed by enzyme-linked immunosorbent assay (ELISA) binding antibody
|
At 21 days post boost vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Solicited Local and Systemic Adverse Events (AEs)
Time Frame: Up to 7 days after each vaccination
|
Up to 7 days after each vaccination
|
|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to 42 days post boost vaccination
|
Up to 42 days post boost vaccination
|
|
Immune Responses to the Study Vaccine Regimens against Ebola virus (EBOV) Glycoprotein (GP) using EBOV GP protein Enzyme-linked Immunosorbent Assay (ELISA)
Time Frame: At Days 1, 29, 57 post prime dose and at days 42, and 180 post boost vaccination
|
The humoral immune response will be assessed by enzyme-linked immunosorbent assay (ELISA) binding antibody
|
At Days 1, 29, 57 post prime dose and at days 42, and 180 post boost vaccination
|
Number of Participants with Serious Adverse Events (SAEs)
Time Frame: Continuous throughout the duration of study (Up to Day 237)
|
Continuous throughout the duration of study (Up to Day 237)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial, Janssen Vaccines & Prevention B.V.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 21, 2015
Primary Completion (Actual)
June 7, 2016
Study Completion (Actual)
November 29, 2016
Study Registration Dates
First Submitted
September 4, 2015
First Submitted That Met QC Criteria
September 4, 2015
First Posted (Estimated)
September 7, 2015
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 7, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
- Safety
- Immunogenicity
- Healthy participants
- Ebola vaccine
- Ebola viruses
- Filoviruses
- Monovalent vaccine
- Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
- Ebola virus disease (EVD)
- Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo)
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR107861
- VAC52150EBL3002 (Other Identifier: Janssen Vaccines & Prevention B.V.)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Ad26.ZEBOV 5*10^10 viral particles (vp)
-
Janssen Vaccines & Prevention B.V.Completed
-
Janssen Vaccines & Prevention B.V.Completed
-
Janssen Vaccines & Prevention B.V.CompletedRespiratory Tract Infections | Respiratory Syncytial VirusesUnited Kingdom, Finland, United States
-
Janssen Vaccines & Prevention B.V.Completed
-
Crucell Holland BVThe PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...Completed
-
London School of Hygiene and Tropical MedicineUniversity of Sierra Leone; Innovative Medicines InitiativeCompletedEbola Virus DiseaseSierra Leone
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome TrustCompletedEbola | Ebola ZaireUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
University of OxfordNational Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...CompletedPlasmodium Falciparum MalariaUnited Kingdom
-
Ahmad TarhiniNovartis PharmaceuticalsTerminatedSmall Cell Lung CancerUnited States